Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-PRIME pragmatic factorial trial in African children with sickle cell disease
ISRCTN15724013Phase 3Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyurea, dihydroartemisinin + piperaquine and trimethoprim + sulfamethoxazole in sickle cell disease (SCD) (6 arms), sponsored by Imperial College London. Primary endpoints: Mortality, Malaria-associated hospitalizations and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
hydroxyureadihydroartemisinin + piperaquinetrimethoprim + sulfamethoxazole
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on ISRCTN15724013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15724013.